GT Gain Therapeutics SA

Follow us

  • LinkedIn Social Icon


Roberto De Ponti, PharmD


Khalid Islam, PhD


  • Grey LinkedIn Icon

Dr. Islam has over 30 years of Pharma and Biotech industry experience. He is currently the Chairman of the Board of Directors of Fennec Pharmaceuticals,and Minoryx Therapeutics S.L. and a member of the Board of Directors of Immunomedics Inc. He has been the Chairman and CEO of Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where, under his leadership Defitelio was granted Marketing Authorisation and the company value increased from 25m USD leading to all cash 1billion USD merger with Jazz Pharmaceuticals, plc. From 1999-2008, he was President and CEO of Arpida AG where he transitioned the early-stage start-up to a SWX-listed company and raised 300m USD in the IPO and follow-ons. From 1987-1999, he held various positions in HMR & MMD (now Sanofi-Aventis). Previously, he has been a member of the Board of Directors of Karolinska Development, Molmed, OxThera, Arpida AG , Rheoscience AS; PCovery AS, Adenium AS and C10 Pharma AS. He is also as an advisor to Kurma Biofund (Paris).

Lorenzo Leoni, PhD

Vice Chairman

  • Grey LinkedIn Icon

Dr. Leoni has more than 20 years of drug development experience. He is currently Managing Partner of TiVenture. He is a scientific serial entrepreneur and founder of several biomedical companies in the US and in Europe (Salmedix Inc, Telormedix SA, Elion Oncology Inc, Oculox Technologies SA, BioPharmaTi Ltd). He holds Board positions in several technology companies and has an extensive network at the academic, financial and industrial level in Biotech and MedTech. 

Dr. Leoni was an Assistant Professor at the Department of Medicine at UCSD in San Diego, working in the fields of oncology and immunology. He holds a Ph.D. in Biochemistry from the University of Lausanne

  • Grey LinkedIn Icon

Dr. De Ponti is Head of Corporate New Ventures and Strategic Investments for Helsinn International Services, the advisor company to the Helsinn Investment Fund. From 2008 to when he joined the fund in 2016, Dr. De Ponti was Head of Corporate Business Development at Helsinn. Prior joining the Helsinn Group, Dr. De Ponti held responsibilities for in and out-licensing at Indena, and served as Site Lead and Head of Pharmaceutical Sciences at the Oncology Italian site of Pharmacia and Pfizer. Dr. De Ponti has held several patents covering the development and the commercialization of oncology drugs. He is a Pharmacist by training and an EU Qualified Person.

Roberto Barzi


  • Grey LinkedIn Icon

Mr. Barzi is Managing Partner of VitaTech SA. He has been active as an investor in the healthcare sector for over a decade. Initially a member of the global healthcare group at 3i, Roberto then set up Fort Rock Capital, a London-based investor in life sciences. He is currently the managing partner of VitaTech, a Luxembourg based platform focused on pan-European healthtech investments. Roberto sits on the boards of GNS Healthcare (USA, digital health and AI), Vasopharm Gmbh (Germany, traumatic brain injury), Medinet (UK, clinical services) and Algenex (Spain, protein production). He holds an MBA from the Wharton School and a degree in economics from Bocconi University.

Jeffrey Riley

Independent Member

  • Grey LinkedIn Icon

Mr. Riley has more than 25 years of experience in the biotechnology and pharmaceutical industries, during which he has negotiated numerous worldwide strategic corporate alliances, established joint ventures and assisted in venture financings to support product development. He has raised over $1.5B in equity and debt instruments.  He has worked for big pharma (SmithKline Beecham and Pfizer), venture capital (Queensland Biocapital Fund / QIC) and numerous biotechnology companies in their capacity of business development and general management.  He has served on public and private Boards in the USA and Australia. He has a BS degree (Boise State University), a MBA/MIM (Thunderbird/Arizona State) and advanced science work (UC San Francisco/Berkeley)